Leading a new era in bone marrow transplant medicine

We are developing novel medicines to transform all aspects of bone marrow transplant and create a life-saving platform for many diseases.

Learn more
Acute Myeloid Leukemia survivor Gayle. Read her story.
A Curative Vision

We are expanding the curative potential of bone marrow transplant to more patients who can benefit. We are advancing a broad portfolio of products in development, including our most advanced program, MGTA-456, which is currently being studied in Phase 1/2 clinical trials.

Learn more
Focus on Patients

Today bone marrow transplants are complicated, toxic and high-risk. We are working to change that for patients with autoimmune diseases, blood cancers, and rare genetic diseases.

Learn more
Our Culture

What inspires Magenta?
Equal parts Courage, Commitment and Excellence.

Learn more


View all news

Social Media

@MagentaTx September 4, 2019
We're excited to announce that FDA has granted RMAT designation to our MGTA-456 investigational #celltherapy for mu… http://G8s8Astyih

See us on Twitter